SLC2A3 and glioblastoma: GBM cells are unique in their expression of Glut3/14, allowing efficient Gal import and metabolism via the Leloir pathway; as a result, Gal-based antimetabolites will have a differential impact on GBM cells and will have potential in GBM therapy.